Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high risk HER2 positive early breast cancer (DESTINY Breast11): a randomised, open label, multicentre, phase III trial Annals of Oncology The Dihexa story Most hyped brain peptide of the decade. "10,000,000x more potent than BDNF." Based on one paper retracted in 2021. Swipe through all 7 slides. For research purposes only. When will clinical trials finally reflect diversity? Is Dihexa an approved and safe treatment for cognitive impairment or neurodegenerative diseases such as Alzheimer disease? FDA drug trials exclude a widening slice of Americans, research reveals Clinical Trials Dementia Statistics Hub